Join
Live feed
·
PRReleasevia Quantisnow
AbbVie Inc. logo

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

ByQuantisnow·Wall Street's wire, on your screen.
ABBV· AbbVie Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABBV (AbbVie Inc.) and more on Quantisnow.